FY2025 Earnings Estimate for XENE Issued By Chardan Capital

Key Points

• Chardan Capital has reduced its FY2025 earnings per share estimate for Xenon Pharmaceuticals to ($4.30), predicting lower performance compared to their previous estimate of ($4.15).
• The stock currently has a "Moderate Buy" consensus rating, with a price target averaging $53.20 following various ratings from analysts.
• Xenon Pharmaceuticals' shares have experienced fluctuations, with a market cap of $2.95 billion and a reported quarterly EPS loss of ($1.07), missing estimates by ($0.04).

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Chardan Capital decreased their FY2025 earnings estimates for Xenon Pharmaceuticals in a report released on Wednesday, August 13th. Chardan Capital analyst R. Li now forecasts that the biopharmaceutical company will earn ($4.30) per share for the year, down from their prior estimate of ($4.15). Chardan Capital has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Chardan Capital also issued estimates for Xenon Pharmaceuticals' FY2026 earnings at ($2.15) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same period in the prior year, the business posted ($0.75) EPS.

Several other equities research analysts have also recently issued reports on XENE. Needham & Company LLC lowered their target price on shares of Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Evercore ISI started coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They set an "outperform" rating and a $55.00 target price on the stock. Wall Street Zen cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Finally, Wells Fargo & Company lowered their target price on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $53.20.

Xenon Pharmaceuticals Trading Up 1.7%

NASDAQ:XENE traded up $0.66 during trading hours on Monday, reaching $38.84. 1,186,173 shares of the company were exchanged, compared to its average volume of 1,059,102. The stock's 50-day moving average is $33.16 and its 200-day moving average is $33.99. The firm has a market cap of $2.99 billion, a PE ratio of -10.94 and a beta of 1.16. Xenon Pharmaceuticals has a twelve month low of $26.74 and a twelve month high of $46.00.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. L1 Capital Pty Ltd acquired a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth $41,000. Tower Research Capital LLC TRC increased its stake in shares of Xenon Pharmaceuticals by 10,614.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,357 shares of the biopharmaceutical company's stock worth $168,000 after acquiring an additional 5,307 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter worth $2,466,000. Vestal Point Capital LP increased its stake in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after acquiring an additional 700,000 shares during the last quarter. Finally, Oxford Asset Management LLP increased its stake in shares of Xenon Pharmaceuticals by 242.4% in the 2nd quarter. Oxford Asset Management LLP now owns 21,138 shares of the biopharmaceutical company's stock worth $662,000 after acquiring an additional 14,964 shares during the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.